More recently, results from the KRYSTAL-1 phase II study enrolling 116 patients with NSCLC harboring a KRAS c.34G > T (p.G12C) mutation who received adagrasib following prior treatment with immunotherapy and chemotherapy were presented by Spira et al. at the 2022 ASCO annual meeting [179]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.